Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04984330
Other study ID # 21-01023225
Secondary ID
Status Withdrawn
Phase Early Phase 1
First received
Last updated
Start date December 2021
Est. completion date June 2024

Study information

Verified date November 2022
Source Weill Medical College of Cornell University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2024
Est. primary completion date June 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of primary AL amyloidosis - Relapsed and/or refractory AL amyloidosis - Measurable disease - Male or female patients 18 years or older - Able to give voluntary written consent - Eastern Cooperative Oncology Group performance status and/or other performance status 0, 1, or 2. - Absolute neutrophil count (ANC) = 1,000/mm3 and platelet count = 75,000/mm3. - Total bilirubin = 1.5 × the upper limit of the normal range (ULN). - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 × ULN. - Calculated creatinine clearance = 30 mL/min Exclusion Criteria: - Non-AL amyloidosis - Clinically overt myeloma - Prior exposure to Selinexor - Clinically significant cardiac disease - Severe obstructive airway disease - Female patients who are lactating or have a positive serum pregnancy test during the screening period - Planned high-dose chemotherapy and autologous stem cell transplantation within 6, 28-day treatment cycles after starting on treatment - Failure to have fully recovered (ie, = Grade 1 toxicity) from the reversible effects of prior chemotherapy. - Major surgery within 14 days before enrollment. - Radiotherapy within 14 days before enrollment. - Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before study enrollment. Systemic treatment, within 14 days before the first dose, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, see Appendix 11.7), or use of Ginkgo biloba or St. John's wort. - Positive for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C - Serious medical or psychiatric illness - GI disease or GI procedure that could interfere with the oral absorption or tolerance including difficulty swallowing - Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection. - Participation in another clinical trials involving investigational agents within 30 days of starting this trial - Peripheral neuropathy (grade 2 with pain or grade 3 or higher).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Selinexor
Selinexor will be given orally at a dose of 60mg once weekly on the first day of the week (day 1, 8, 15, and 22) for Cycle 1 and up to Cycle 12.
Dexamethasone
Dexamethasone will be given orally at a dose of 20mg, if tolerated, or at a reduced dose if required, 30 to 60 minutes prior to selinexor for first 2 days of each week only (days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).

Locations

Country Name City State
United States Weill Cornell Medicine - Multiple Myeloma Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
Weill Medical College of Cornell University Karyopharm Therapeutics Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compare number of dose limiting toxicity (DLT) occurence to measure safety and toxicity Safety and toxicity will be determined by how many occurrence of dose limiting toxicity (DLT) occured during 12 months of treatment for each subject approximately 12 months
Secondary Compare Hematologic Overall Response Rate (ORR) Comparing proportion of subjects with Complete Response (CR), Very Good Partial Response (VGPR), Partial Response (PR), No Response (NR) and Progressive Disease (PD) approximately 12 months
Secondary Hematologic Very Good Partial Response (VGPR) or better rate Percentage of subjects that achieved Very Good Partial Response (VGPR) or better response approximately 12 months
Secondary Hematologic Complete Response (CR) rate Percentage of subjects that achieved Complete Response (CR) approximately 12 months
Secondary Stringent dFLC response rate Percentage of subjects that has stringent dFLC (dFLC is defined as the difference in involved amyloidogenic and uninvolved serum-free light chains). approximately 12 months
Secondary Number of patients with peripheral blood mass spectrometry for monoclonal protein detection (MALDI-TOF) For each subject, detection of monoclonal protein will be analyzed at screening, day 1 of each cycle (only when in =VGPR), at each end of treatment (EOT) visits, and day 1 of each post-treatment follow, up until PD or 24 months, whichever occurs first. End of Study (approximately 3 years)
Secondary minimal residual disease (MRD) negative CR/VGPR rate Percentage of subjects that is MRD negative when in complete response (CR) and Very Good Partial Response (VGPR) approximately 12 months
Secondary Percentage of participants with organ response Organ response for kidney and cardiac is defined as the proportion of baseline organ involved participants who achieve organ response in each corresponding organ. Organ response defined for cardiac: N-terminal brain pronatriuretic peptide (NT-proBNP) response (> 30% and > 300 nanogram per liter [ng/L] decrease in participants with baseline NT-proBNP >= 650 ng/L) or New York Heart Association (NYHA) class response (>= 2 class decrease in participants with baseline NYHA class 3 or 4); for kidney: decrease in proteinuria by >=30% or below 0.5 grams /24 hours without renal progression. End of Study (approximately 3 years)
Secondary Median hematologic Progression Free Survival (PFS) Median estimate of months that participants have progression free survival and median estimate is calculated using the Kaplan-Meier methodology End of Study (approximately 3 years)
Secondary Time to first hematologic response Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met the criteria for hematologic complete response. approximately 12 months
Secondary Time to best hematologic response Measured in months between the date of enrollment and the best hematologic response the subject achieved while on treatment approximately 12 months
Secondary Time to hematologic progression Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met the criteria for hematologic progression End of Study (approximately 3 years)
Secondary Duration of hematologic response Duration of hematologic response is defined as the time between the date of initial documentation of hematologic response (i.e. Complete Response, Very Good Partial Response, Partial Response, No Response and Progressive Disease) to the date of the next hematologic response End of Study (approximately 3 years)
Secondary Time to next therapy Measured in months from the date of enrollment to the start date of subsequent treatment for AL amyloidosis End of Study (approximately 3 years)
Secondary Median organ Progression Free Survival (PFS) Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met the criteria for hematologic complete response. End of Study (approximately 3 years)
Secondary Time to organ response Measured in months between the date of enrollment and the organ response approximately 12 months
Secondary Time to organ progression Measured in months between the date of organ response to organ progression End of Study (approximately 3 years)
Secondary Duration of organ response Measured in months between the date of initial documentation of organ response to organ progression End of Study (approximately 3 years)
See also
  Status Clinical Trial Phase
Recruiting NCT04893889 - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease. N/A
Withdrawn NCT04943302 - Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis Phase 2
Active, not recruiting NCT02909036 - Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. Phase 1
Completed NCT02816476 - Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis Phase 2
Completed NCT01083316 - Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis Phase 2
Completed NCT01527032 - Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis Phase 2
Completed NCT02545907 - A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis Phase 1/Phase 2
Recruiting NCT05263817 - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis Early Phase 1
Active, not recruiting NCT03201965 - A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis Phase 3
Withdrawn NCT02589860 - Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT02574676 - Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Active, not recruiting NCT02260466 - Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. N/A
Withdrawn NCT02462213 - Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging N/A
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Completed NCT01406314 - SAP Depleter Dose Assessment Study in Patients Phase 1
Not yet recruiting NCT04985734 - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy N/A
Active, not recruiting NCT03584022 - Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial N/A
Active, not recruiting NCT05199337 - Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis Phase 1/Phase 2
Active, not recruiting NCT05235269 - A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis Phase 2